JP5473432B2 - マイクロrna分子 - Google Patents
マイクロrna分子 Download PDFInfo
- Publication number
- JP5473432B2 JP5473432B2 JP2009155226A JP2009155226A JP5473432B2 JP 5473432 B2 JP5473432 B2 JP 5473432B2 JP 2009155226 A JP2009155226 A JP 2009155226A JP 2009155226 A JP2009155226 A JP 2009155226A JP 5473432 B2 JP5473432 B2 JP 5473432B2
- Authority
- JP
- Japan
- Prior art keywords
- mirna
- mir
- nucleic acid
- acid molecule
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/10—Production naturally occurring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Description
(a)第1表、第2表、第3表又は第4表に示されているようなヌクレオチド配列、
(b)(a)の補体であるヌクレオチド配列、
(c)(a)又は(b)の配列に対して少なくとも80%、有利には少なくとも90%及びより有利には少なくとも99%のアイデンティティを有するヌクレオチド配列及び/又は
(d)ストリンジェント条件下に、(a)、(b)及び/又は(c)の配列にハイブリダイズするヌクレオチド配列
を有する単離された核酸分子に関する。
I=n:L
[ここで、Iはアイデンティティ(%)であり、nは所定の配列と第1表、第2表、第3表又は第4表に示されているような比較配列との間の同じヌクレオチドの数であり、Lは比較配列の長さである]。第1、2、3及び4表に描かれているようなヌクレオチドA、C、G及びUは、リボヌクレオチド、デオキシリボヌクレオチド及び/又は他のヌクレオチド類似体、即ち合成の非天然由来のヌクレオチド類似体を意味することができる。更に、ヌクレオ塩基は、相補的核酸配列への類似H−結合を形成することのできる相応するヌクレオ塩基により置換されることができ、例えば、UはTで置換されていてよい。
本発明者は、以前に、キイロショウジョウバエ(Drosophila melanogaster)胚リゼート中での長いdsRNAのプロセッシングの後のsiRNAを単離するために、方向性クローニング法を開発した(8)。簡単にいえば、5’及び3’アダプター分子をサイズ−分別されたRNA集団の末端にライゲートさせ、引き続き、逆転写、PCR増幅、コンカテマー化、クローニング及びシークエンシングを行った。元来siRNAを単離するために意図されたこの方法は、14の新規20−〜23−ntの短かいRNA(これらはキイロショウジョウバエゲノムでコードされ、かつ0〜2h胚中に発現されている)の同時同定をもたらした(第1表)。この方法は、HeLa細胞全RNAからの類似サイズ範囲内のクローンRNAに適応され、これは19の新規ヒトstRNAの同定をもたらし(第2表)、従って、更に、潜在的調節役割を有する小さいRNAの大クラスの存在の証拠を提供していた。それらの小さいサイズに従って、これらの新規RNAをマイクロRNA又はmiRNAと称する。これらのmiRNAは、miR−1〜miR−33と略記され、この遺伝子をコードしているmiRNAは、mir−1〜mir−33と名付けられている。高い相同性のmiRNAが、小文字の付加、引き続くダッシュ及びmir遺伝子のマルチプルゲノミックコピーを指名する番号により分類されている。
哺乳動物中のmiRNAの分布及び機能へのより詳細な洞察を得るために、成熟マウスでのmiRNAの組織−特異的分布を調査した。通常はノーザンブロット分析で検出されない低量miRNAはクローン的に同定されるので、特異組織からのmiRNAのクローニングを、全体の生物−ベースクローニングに渡って実施した。21−ntRNAを検出するためのin situ ハイブリダイゼーシヨン法は、未だ開発されてもいない。従って、18.5週齢BL6マウスから単離された全RNAから19−〜25−ヌクレオチドRNAをクローニングし、かつシークエンシングした。miRNAのクローニングを次のように実施した:全RNAの0.2〜1mgを15%変性ポリアクリルアミドゲル上で分離し、19−〜25−ntサイズのRNAを回収した。5’−リン酸化された3’−アダプターオリゴヌクレオチド(5’−pUUUaaccgcgaattccagx:大文字はRNA;小文字はDNA;pはホスフェート;xは3’−アミノ−モディファイアーC−7、ChemGenes,Ashland,Ma,USA,Cat.No.NSS−1004;SEQ ID NO:54)及び5’−アダプターオリゴヌクレオチド(5’−acggaattcctcactAAA:大文字はRNA;小文字はDNA;SEQ ID NO:55)を短かいRNAにライゲートさせた。RT/PCRを、3’−プライマー(5’−GACTAGCTGGAATTCGCGGTTAAA;SEQ ID NO:56)及び5’−プライマー(5’−CAGCCAACGGAATTCCTCACTAAA;SEQ ID NO:57)を用いて実施した。BanI制限部位を導入するために、プライマー対5’−CAGCCAACAGGCACCGAATTCCTCACTAAA(SEQ ID NO:57)及び5’−GACTAGCTTGGTGCCGAATTCGCGGTTAAA(SEQ ID NO:56)を用いて第2PCRを実施し、引き続きBan I消化の後のコンカテマー化及びT4DNAライゲーションを行った。400〜600塩基対のコンカテマーを、1.5%アガロースゲルから切出し、バイオトラップ(Schleicher & Schuell)電気溶出(1×TAEバッファ)及びエタノール沈殿により回収した。引き続き、このコンカテマーの3’末端を、72℃で、Taqポリメラーゼと一緒の15分間インキュベーシヨンにより、充填した。この溶液を水で3倍に希釈し、直接、pCR2.1 TOPOベクター中へのライゲーションのために使用した。クローンをPCRでの挿入のためにスクリーニングし、30〜50試料をシークエンシングに供した。RNAが数匹のマウスの結合組織から製造されたので、多クローン中で複数回検出された微量配列変異は、RT/PCR突然変異よりもむしろ多型を反映しているらしい。約21−ntのRNAをコードするゲノム配列の同定のためにパブリックデータベースサ−チングを使用した。隣接上流又は下流フランキング配列を包含する20〜30塩基対フォールド−バック構造の発生が、miRNAを指定するために用いられた[36−38]。
キイロショウジョウバエmiRNA。与えられている配列は、クローニングにより同定された最も豊富で、かつ典型的な最長のmiRNA配列を表し;miRNAは、屡々その3’末端で1又は2個のヌクレオチドの長さで変動する。シークエンシングされた222の短かいRNAのうち、69(31%)はmiRNAに、103(46%)は既にキャラクテライズされた機能的RNA(rRNA、7SLRNA、tRNA)に、30(14%)はトランスポゾンRNAフラグメントに、かつ20(10%)はデータベース登録のない配列に相当した。全ての同定されたmiRNAに関連している特別なmiRNAをクローニングの頻度(freq)が、パーセントで示されている。キイロショウジョウバエの段階集団から単離された全RNAのノーザンブロッティングの結果がまとめられている。Eは胚;Lは幼虫段階;Pは蛹;Aは成虫:S2はSchneider−2細胞。各ブロットのシグナルの強さは、最強(+++)〜非検出(−)で表されている。対照としてlet−7stRNAを検査した。他の種中でのデータベースサーチングにより同定された遺伝子バンクアクセッシヨン番号及びmiRNAの相同体が補助的マテリアルとして提供されている。
ヒトmiRNA。シークエンシングされた220の短かいRNAのうち、100(45%)はmiRNAに、53(24%)は既にキャラクテライズされた機能的RNA(rRNA、snRNA、tRNA)に、かつ67(30%)はデータベース登録のない配列に相当した。異なる脊椎動物種及びS2から単離された全RNAのノーザンブロッティングの結果が示されている。説明に関しては第1表を参照。
マウスmiRNA。指示されている配列は、クローニングにより同定された最長のmiRNA配列を表す。miRNAの3’−末端は、屡々1又は2個のヌクレオチドで先端切断されている。85%(即ち、21ヌクレオチドの18を占める)より多くが配列において同じであるか又は1−又は2−ヌクレオチド内部欠失を有するmiRNAは、同じ遺伝子番号、引き続く小文字で記載されている。関連miRNAの間の微量配列変異は、一般にmiRNA配列の末端近くに見出され、ターゲットRNA認識を害しないと考えられている。微量配列変異は、ターゲット認識の間にG−Uゆらぎ塩基対として適応されるAからGへ及びCからUへの変化をも表すことができる。末尾の−s又は−asを有するmiRNAは、miRNA前駆体の5’−ハーフ又は3’−ハーフのいずれかから誘導されたRNAを示している。マウス脳を中脳mb、皮質cx、小脳cb中まで解剖した。分析された組織は、心臓ht;肝臓lv;小腸si;結腸co;皮質ct;小脳cb;中脳mbであった。
マウス及びヒトmiRNA。指示されている配列は、クローニングにより同定された最長のmiRNA配列を表している。miRNAの3’末端は、屡々1又は2個のヌクレオチドで先端切断されている。85%(即ち21ヌクレオチドの18を占める)より多くが配列において同じであるか、又は1−又は2−ヌクレオチド内部欠失を有するmiRNAが、同じ遺伝子番号、引き続く小文字で記載されている。関連miRNAの間の微量配列変異は、一般にmiRNA配列の末端近くに見出され、ターゲットRNA認識を害しないと考えられている。微量配列変異は、ターゲット認識の間のG−Uゆらぎ塩基対として適応されるAからG及びCからUへの変化をも表すこともできる。マウス脳を中脳mb;皮質cx;小脳cb中まで解剖した。分析された組織は、肺ln;肝臓lv;脾臓sp;腎臓kd;皮膚sk;精巣ts;卵巣ov;胸腺thy;眼ey;皮質ct;小脳cb;中脳mbであった。ヒト骨肉腫細胞SAOS−2細胞は、誘導可能なp53遺伝子(p53−は誘導されていないp53;p53+は誘導されたp53)を含有し、誘導された及び誘導されていないSAOS細胞から同定されたmiRNA中の差異は、統計的に有意ではなかった。
キイロショウジョウバエmiRNA配列及びゲノム位置。挙げられている配列は、クローニングにより同定された最も豊富でかつ典型的な最長のmiRNA配列を表している。miRNAsは、それらの3’−末端で1又は2個のヌクレオチドの長さで変動することが屡々観察された。シークエンシングされた222の短かいRNAのうち、69(31%)はmiRNAに、103(14%)は既にキャラクテライズされた機能的RNA(rRNA、7SLRNA、tRNA)に、30(14%)はトランスポゾンRNAフラグメントに、かつ20(10%)はデータベース登録のない配列に相当していた。5’−グアノシンを有するRNA配列は、クローニング操作の故に、おそらく他より少ない(8)。他の種中に見出されたmiRNA相同体が指示されている。染色体位置(chr)及び遺伝子バンクアクセッシヨン番号(acc.nb.)が示されている。データベースサーチングによってESTマッチングmiR−1〜miR−4は検出不能であった。
ヒトmiRNA配列及びゲノム位置。シークエンシングされた220の短かいRNAのうち、100(45%)はmiRNAsに、53(24%)は既にキャラクテライズされた機能的RNA(rRNA、snRNA、tRNA)に、かつ67(39%)はデータベース登録のない配列に相当した。
Claims (10)
- (a)配列番号88に示されているヌクレオチド配列、
(b)(a)の相補体であるヌクレオチド配列、又は
(c)(a)又は(b)の配列に対して少なくとも90%のアイデンティティを有する、癌細胞同定のためのヌクレオチド配列
を有し、18〜25ヌクレオチドの長さを有する単離された核酸分子。 - 配列(c)のアイデンティティが少なくとも95%である、請求項1に記載の核酸分子。
- miRNAである請求項1又は2に記載の核酸分子のmiRNA前駆体分子であって、かつ、60〜80ヌクレオチドの長さを有するmiRNA前駆体分子又はそれをコードするDNA分子。
- 一本鎖である、請求項1又は2に記載の核酸分子。
- 少なくとも部分的に二本鎖である、請求項1又は2に記載の核酸分子。
- RNA、DNA又は糖−若しくは骨格−修飾リボヌクレオチド、デオキシリボヌクレオチド、ペプチド核酸(PNA)若しくはロックド核酸(LNA)から選択されている、請求項1、2、4、5のいずれか1項に記載の核酸分子。
- 少なくとも1個の糖−又は骨格−修飾リボヌクレオチドを含有する分子である、請求項6に記載の核酸分子。
- 請求項6に記載の核酸分子を含む、組み換え発現ベクター。
- 活性薬剤としての請求項1、2、4−7のいずれか1項に記載の核酸分子少なくとも1種及び場合により薬剤学的に認容性の賦形剤を含有する、癌細胞のin vivo同定のためのマーカー組成物。
- サイズ−分別されたRNA集団の末端への5’−及び3’−アダプター分子のライゲーション、前記アダプターでライゲーションされたRNA集団の逆転写及びこの逆転写産生物のキャラクテライゼーションからなる、請求項1、2、4−7のいずれか1項記載の核酸分子を同定する方法。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01123453 | 2001-09-28 | ||
EP01123453.1 | 2001-09-28 | ||
EP02006712 | 2002-03-22 | ||
EP02006712.0 | 2002-03-22 | ||
EP02016772 | 2002-07-26 | ||
EP02016772.2 | 2002-07-26 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003532675A Division JP4371812B2 (ja) | 2001-09-28 | 2002-09-27 | マイクロrna分子 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013249347A Division JP5963735B2 (ja) | 2001-09-28 | 2013-12-02 | マイクロrna分子 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009278981A JP2009278981A (ja) | 2009-12-03 |
JP5473432B2 true JP5473432B2 (ja) | 2014-04-16 |
Family
ID=27224236
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003532675A Expired - Fee Related JP4371812B2 (ja) | 2001-09-28 | 2002-09-27 | マイクロrna分子 |
JP2009155226A Expired - Lifetime JP5473432B2 (ja) | 2001-09-28 | 2009-06-30 | マイクロrna分子 |
JP2013249347A Expired - Lifetime JP5963735B2 (ja) | 2001-09-28 | 2013-12-02 | マイクロrna分子 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003532675A Expired - Fee Related JP4371812B2 (ja) | 2001-09-28 | 2002-09-27 | マイクロrna分子 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013249347A Expired - Lifetime JP5963735B2 (ja) | 2001-09-28 | 2013-12-02 | マイクロrna分子 |
Country Status (7)
Country | Link |
---|---|
US (12) | US7232806B2 (ja) |
EP (15) | EP1430128B1 (ja) |
JP (3) | JP4371812B2 (ja) |
AU (1) | AU2002347035B2 (ja) |
CA (2) | CA2937159C (ja) |
IL (3) | IL161100A0 (ja) |
WO (1) | WO2003029459A2 (ja) |
Families Citing this family (422)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001249622B2 (en) * | 2000-03-30 | 2007-06-07 | Massachusetts Institute Of Technology | RNA sequence-specific mediators of RNA interference |
KR100909681B1 (ko) | 2000-12-01 | 2009-07-29 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | Rna 간섭을 매개하는 작은 rna 분자 |
US20020142304A1 (en) * | 2001-03-09 | 2002-10-03 | Anderson Daniel G. | Uses and methods of making microarrays of polymeric biomaterials |
EP2360251B1 (en) * | 2001-07-12 | 2016-09-28 | University of Massachusetts | In vivo production of small interfering RNAs that mediate gene silencing |
PT1504126E (pt) | 2002-05-03 | 2014-06-02 | Univ Duke | Um método para regular a expressão génica |
JP2005532053A (ja) | 2002-07-01 | 2005-10-27 | ウエイン・ステイト・ユニバーシテイ | 抗生物質耐性を起こしやすくない抗生物質の同定のための方法および組成物 |
WO2004014933A1 (en) | 2002-08-07 | 2004-02-19 | University Of Massachusetts | Compositions for rna interference and methods of use thereof |
US20040219565A1 (en) | 2002-10-21 | 2004-11-04 | Sakari Kauppinen | Oligonucleotides useful for detecting and analyzing nucleic acids of interest |
US7892793B2 (en) * | 2002-11-04 | 2011-02-22 | University Of Massachusetts | Allele-specific RNA interference |
WO2004043387A2 (en) * | 2002-11-13 | 2004-05-27 | Thomas Jefferson University | Compositions and methods for cancer diagnosis and therapy |
US8163896B1 (en) | 2002-11-14 | 2012-04-24 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
US7655785B1 (en) | 2002-11-14 | 2010-02-02 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof |
US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
US7906326B2 (en) * | 2003-05-07 | 2011-03-15 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides associated with alzheimer's disease and uses thereof |
AU2003298718A1 (en) * | 2002-11-22 | 2004-06-18 | University Of Massachusetts | Modulation of hiv replication by rna interference |
US7217807B2 (en) | 2002-11-26 | 2007-05-15 | Rosetta Genomics Ltd | Bioinformatically detectable group of novel HIV regulatory genes and uses thereof |
US20040167090A1 (en) * | 2003-02-21 | 2004-08-26 | Monahan Sean D. | Covalent modification of RNA for in vitro and in vivo delivery |
BRPI0409895B8 (pt) * | 2003-05-09 | 2021-05-25 | Crucell Holland Bv | método de cultura de células derivadas de células per.c6 capazes de crescer em suspensão para aumentar o rendimento de produto das referidas células |
US9453219B2 (en) * | 2003-05-15 | 2016-09-27 | Mello Biotech Taiwan Co., Ltd. | Cosmetic designs and products using intronic RNA |
DE602004029678D1 (de) * | 2003-06-02 | 2010-12-02 | Univ Massachusetts | Verfahren und zusammensetzungen zur verbesserung der wirksamkeit und spezifität von fnai |
US7459547B2 (en) * | 2003-06-02 | 2008-12-02 | University Of Massachusetts | Methods and compositions for controlling efficacy of RNA silencing |
US7750144B2 (en) * | 2003-06-02 | 2010-07-06 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNA silencing |
US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
WO2005047505A2 (en) * | 2003-08-07 | 2005-05-26 | Whitehead Institute For Biomedical Research | Methods and products for expression of micro rnas |
US7888497B2 (en) | 2003-08-13 | 2011-02-15 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof |
US8680063B2 (en) | 2003-09-12 | 2014-03-25 | University Of Massachusetts | RNA interference for the treatment of gain-of-function disorders |
WO2005027980A1 (en) * | 2003-09-12 | 2005-03-31 | University Of Massachusetts | Rna interference for the treatment of gain-of-function disorders |
WO2005054494A2 (en) | 2003-11-26 | 2005-06-16 | University Of Massachusetts | Sequence-specific inhibition of small rna function |
WO2005056797A1 (en) * | 2003-12-15 | 2005-06-23 | Kye-Seong Kim | Novel mirna molecules isolated from human embryonic stem cell |
US20060134787A1 (en) | 2004-12-22 | 2006-06-22 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA |
CA2554818A1 (en) | 2004-02-09 | 2005-08-25 | Thomas Jefferson University | Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features |
US20050186606A1 (en) * | 2004-02-11 | 2005-08-25 | Schroeder Benjamin G. | Methods and compositions for detecting nucleic acids |
US20050182005A1 (en) | 2004-02-13 | 2005-08-18 | Tuschl Thomas H. | Anti-microRNA oligonucleotide molecules |
WO2005079397A2 (en) | 2004-02-13 | 2005-09-01 | Rockefeller University | Anti-microrna oligonucleotide molecules |
WO2005079532A2 (en) * | 2004-02-17 | 2005-09-01 | University Of Massachusetts | Methods and compositions for enhancing risc activity in vitro and in vivo |
US20060069050A1 (en) * | 2004-02-17 | 2006-03-30 | University Of Massachusetts | Methods and compositions for mediating gene silencing |
US7943754B2 (en) * | 2004-04-02 | 2011-05-17 | Rosetta-Genomics | Bioinformatically detectable group of novel regulatory bacterial and bacterial associated oligonucleotides and uses thereof |
US8088902B2 (en) | 2004-04-05 | 2012-01-03 | The Rockefeller University | DNA virus microRNA and methods for inhibiting same |
US7416842B2 (en) | 2004-04-05 | 2008-08-26 | The Rockefeller University | DNA virus microRNA |
US20050260648A1 (en) * | 2004-04-06 | 2005-11-24 | Huffel Christophe V | Method for the determination of cellular transcriptional |
US20060134639A1 (en) * | 2004-04-06 | 2006-06-22 | Huffel Christophe V | Method for the determination of cellular transcriptional regulation |
US7365058B2 (en) | 2004-04-13 | 2008-04-29 | The Rockefeller University | MicroRNA and methods for inhibiting same |
EP2338996A3 (en) | 2004-05-04 | 2013-12-18 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for reducing viral genome amounts in a target cell |
US7593483B2 (en) * | 2004-05-07 | 2009-09-22 | Broadcom Corporation | Nonlinear mapping in digital-to-analog and analog-to-digital converters |
EP1784501B1 (en) * | 2004-05-14 | 2015-11-18 | Rosetta Genomics Ltd | VIRAL AND VIRUS ASSOCIATED MicroRNAS AND USES THEREOF |
US7687616B1 (en) | 2004-05-14 | 2010-03-30 | Rosetta Genomics Ltd | Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof |
US8563252B2 (en) * | 2004-05-14 | 2013-10-22 | Rosetta Genomics Ltd. | Methods for distinguishing between lung squamous carcinoma and other non small cell lung cancers |
US7795419B2 (en) | 2004-05-26 | 2010-09-14 | Rosetta Genomics Ltd. | Viral and viral associated miRNAs and uses thereof |
WO2005118806A2 (en) * | 2004-05-28 | 2005-12-15 | Ambion, Inc. | METHODS AND COMPOSITIONS INVOLVING MicroRNA |
AU2005272816B2 (en) | 2004-08-10 | 2011-08-11 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides |
EP1789592A4 (en) * | 2004-08-13 | 2009-12-23 | Univ Delaware | METHOD FOR IDENTIFYING AND QUANTIFYING SHORT OR SMALL ARN |
AU2005282731B2 (en) * | 2004-09-02 | 2010-04-01 | Yale University | Regulation of oncogenes by microRNAs |
EP1791954A1 (en) * | 2004-09-07 | 2007-06-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial |
FR2877350B1 (fr) * | 2004-11-03 | 2010-08-27 | Centre Nat Rech Scient | IDENTIFICATION ET UTILISATION DE miRNAs IMPLIQUES DANS LA DIFFERENCIATION DE CELLULES ISSUES D'UNE LEUCEMIE MYELOIDE |
CA2850323A1 (en) * | 2004-11-12 | 2006-12-28 | Asuragen, Inc. | Methods and compositions involving mirna and mirna inhibitor molecules |
US20060200878A1 (en) * | 2004-12-21 | 2006-09-07 | Linda Lutfiyya | Recombinant DNA constructs and methods for controlling gene expression |
EP1838870A2 (en) * | 2004-12-29 | 2007-10-03 | Exiqon A/S | NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF MICRORNAS AND THEIR TARGET MRNAs |
US8192938B2 (en) | 2005-02-24 | 2012-06-05 | The Ohio State University | Methods for quantifying microRNA precursors |
US20070065840A1 (en) * | 2005-03-23 | 2007-03-22 | Irena Naguibneva | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS |
US20060223066A1 (en) | 2005-03-29 | 2006-10-05 | Applera Corporation | Methods for normalizing and for identifying small nucleic acids |
EP1877557A2 (en) | 2005-04-04 | 2008-01-16 | The Board of Regents of The University of Texas System | Micro-rna's that regulate muscle cells |
WO2006113743A2 (en) * | 2005-04-18 | 2006-10-26 | Massachusetts Institute Of Technology | Compositions and methods for rna interference with sialidase expression and uses thereof |
EP2631292A3 (en) * | 2005-04-29 | 2013-11-20 | The Rockefeller University | Human microRNAs and methods for inhibiting same |
JP2008539731A (ja) * | 2005-05-02 | 2008-11-20 | コールド スプリング ハーバー ラボラトリー | 癌の診断及び治療のための組成物及び方法 |
US8293517B2 (en) | 2005-05-11 | 2012-10-23 | Wayne State University | Methods and compositions for the identification of antibiotics that are not susceptible to antibiotic resistance in Pseudomonas aeruginosa |
CA2608093A1 (en) | 2005-05-11 | 2006-11-16 | Wayne State University | Novel targets for the identification of antibiotics that are not susceptible to antibiotic resistance |
CN101287834B (zh) | 2005-05-27 | 2016-11-09 | 圣拉法埃莱医院有限公司 | 基因载体 |
JP5777846B2 (ja) * | 2005-06-15 | 2015-09-09 | マサチューセッツ インスティテュート オブ テクノロジー | アミン含有脂質およびその使用 |
US20070111227A1 (en) * | 2005-07-28 | 2007-05-17 | Green Pamela J | Small regulatory RNAs and methods of use |
CN103866017B (zh) * | 2005-08-01 | 2016-05-25 | 俄亥俄州立大学研究基金会 | 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物 |
US20070213292A1 (en) * | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
AU2006279906B2 (en) * | 2005-08-10 | 2012-05-10 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
AU2006279280A1 (en) | 2005-08-18 | 2007-02-22 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating neurological disease |
US20090203893A1 (en) | 2005-08-29 | 2009-08-13 | Regulus Therapeutics, Llc | Antisense compounds having enhanced anti-microrna activity |
JP5523705B2 (ja) * | 2005-08-29 | 2014-06-18 | レグルス・セラピューティクス・インコーポレイテッド | Mir−122aをモジュレートする使用方法 |
WO2007028030A2 (en) * | 2005-09-02 | 2007-03-08 | Picobella, Llc | Oncogenic regulatory rnas for diagnostics and therapeutics |
ES2523989T3 (es) * | 2005-09-12 | 2014-12-03 | The Ohio State University Research Foundation | Composiciones para la terapia de cánceres asociados con BCL2 |
JP2007082436A (ja) * | 2005-09-20 | 2007-04-05 | Bioinformatics Institute For Global Good Inc | 機能性RNAが制御するターゲットmRNAの予測・同定方法及びその利用方法 |
AU2006302496A1 (en) * | 2005-10-05 | 2007-04-19 | The Ohio State University Research Foundation | WWOX gene, vectors containing the same, and uses in treatment of cancer |
CA2634046A1 (en) * | 2005-12-12 | 2007-06-21 | The University Of North Carolina At Chapel Hill | Micrornas that regulate muscle cell proliferation and differentiation |
US7390792B2 (en) * | 2005-12-15 | 2008-06-24 | Board Of Regents, The University Of Texas System | MicroRNA1 therapies |
WO2007081720A2 (en) | 2006-01-05 | 2007-07-19 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer |
AU2007205257B2 (en) * | 2006-01-05 | 2013-07-25 | The Ohio State University Research Foundation | MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors |
EP2487253B1 (en) | 2006-01-05 | 2015-06-24 | The Ohio State University Research Foundation | MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers |
WO2007081204A2 (en) * | 2006-01-10 | 2007-07-19 | Koninklijke Nederlandse Akademie Van Wetenschappen | Nucleic acid molecules and collections thereof, their application and modification |
WO2007081196A1 (en) * | 2006-01-10 | 2007-07-19 | Koninklijke Nederlandse Akademie Van Wetenschappen | New nucleic acid molecules and collections thereof, their application and identification |
US8129515B2 (en) | 2006-01-27 | 2012-03-06 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of microRNAs |
WO2007103808A2 (en) * | 2006-03-02 | 2007-09-13 | The Ohio State University | Microrna expression profile associated with pancreatic cancer |
EP1996731A2 (en) * | 2006-03-20 | 2008-12-03 | The Ohio State University Research Foundation | Microrna fingerprints during human megakaryocytopoiesis |
US8207325B2 (en) | 2006-04-03 | 2012-06-26 | Univ. of Copenhagen | MicroRNA biomarkers for human breast and lung cancer |
EA201100813A1 (ru) | 2006-04-03 | 2012-06-29 | Сантарис Фарма А/С | Фармацевтическая композиция |
CA3024953A1 (en) | 2006-04-03 | 2007-10-11 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
US7955848B2 (en) * | 2006-04-03 | 2011-06-07 | Trustees Of Dartmouth College | MicroRNA biomarkers for human breast and lung cancer |
WO2007131699A2 (en) | 2006-05-12 | 2007-11-22 | Bayer Bioscience N.V. | Novel stress-related microrna molecules and uses thereof |
US20090023221A1 (en) * | 2006-05-19 | 2009-01-22 | Exigon A/S | Oligonucleotide probes useful for detection and analysis of microrna precursors |
US9150626B2 (en) * | 2006-06-02 | 2015-10-06 | President And Fellows Of Harvard College | Protein surface remodeling |
WO2007147067A2 (en) * | 2006-06-14 | 2007-12-21 | Rosetta Inpharmatics Llc | Methods and compositions for regulating cell cycle progression |
US20100292299A1 (en) * | 2006-06-20 | 2010-11-18 | Mendell Joshua T | Nucleotide Motifs Providing Localization Elements and Methods of Use |
ES2447850T3 (es) | 2006-07-13 | 2014-03-13 | The Ohio State University Research Foundation | Métodos y composiciones basados en micro-ARN para el pronóstico y tratamiento de enfermedades relacionadas con el colon |
US7572585B2 (en) * | 2006-07-31 | 2009-08-11 | Agilent Technologies, Inc. | Enzymatic labeling of RNA |
AU2007281261B2 (en) * | 2006-08-01 | 2013-03-21 | Board Of Regents Of The University Of Texas System | Identification of a micro-RNA that activates expression of beta-myosin heavy chain |
US8071292B2 (en) * | 2006-09-19 | 2011-12-06 | The Ohio State University Research Foundation | Leukemia diagnostic methods |
US8343719B2 (en) * | 2006-10-30 | 2013-01-01 | Research Foundation Of State University Of New York | Microrna as biomarker in cancer |
US8252538B2 (en) | 2006-11-01 | 2012-08-28 | The Ohio State University | MicroRNA expression signature for predicting survival and metastases in hepatocellular carcinoma |
DK2104737T3 (da) * | 2006-12-08 | 2013-05-27 | Asuragen Inc | Funktioner og formål for let-7 mikro-RNAer |
EP2104734A2 (en) * | 2006-12-08 | 2009-09-30 | Asuragen, INC. | Mir-20 regulated genes and pathways as targets for therapeutic intervention |
WO2008079303A2 (en) * | 2006-12-20 | 2008-07-03 | The Brigham And Women's Hospital, Inc. | Detection of organ rejection |
US20100086928A1 (en) * | 2006-12-20 | 2010-04-08 | The Brigham And Women's Hospital, Inc. | Detection of organ rejection |
CA2671270A1 (en) * | 2006-12-29 | 2008-07-17 | Asuragen, Inc. | Mir-16 regulated genes and pathways as targets for therapeutic intervention |
EP2111408A4 (en) * | 2007-01-17 | 2010-02-03 | Univ Johns Hopkins | COMPOSITIONS AND METHODS COMPRISING MICROARNS FOR TREATING NEOPLASIA |
CA2674895A1 (en) * | 2007-01-31 | 2008-08-07 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia (aml) |
WO2008095096A2 (en) | 2007-01-31 | 2008-08-07 | Immune Disease Institute | Let-7 microrna and mimetics thereof as therapeutics for cancer |
EP2115141A4 (en) * | 2007-02-20 | 2010-08-04 | Monsanto Technology Llc | INVERTEBRA MICRO-RNA |
US20120064520A1 (en) | 2007-03-01 | 2012-03-15 | Ranit Aharonov | Diagnosis and prognosis of various types of cancers |
EP2134842A2 (en) * | 2007-03-07 | 2009-12-23 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd | Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial |
WO2008119000A1 (en) * | 2007-03-27 | 2008-10-02 | University Of Iowa Research Foundation | Zinc-finger nuclease and rna interference mediated inactivation of viral genomes |
WO2008127587A2 (en) * | 2007-04-11 | 2008-10-23 | Merck & Co., Inc. | Isolated nucleic acid molecules corresponding to micro rna 145 (mirna-145) and their use in treating colon cancer |
US20090105174A1 (en) * | 2007-04-20 | 2009-04-23 | Amgen Inc. | Nucleic acids hybridizable to micro rna and precursors thereof |
AU2008248319B2 (en) * | 2007-04-30 | 2013-09-05 | The Ohio State University Research Foundation | Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis |
WO2008143774A2 (en) * | 2007-05-01 | 2008-11-27 | University Of Massachusetts | Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy |
US20090131354A1 (en) * | 2007-05-22 | 2009-05-21 | Bader Andreas G | miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
DK2164967T3 (en) * | 2007-05-31 | 2015-10-19 | Univ Iowa Res Found | Reduction of off-target rna interferenstoksicitet |
EP2559773B1 (en) * | 2007-06-08 | 2015-04-22 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Methods for determining a hepatocellular carcinoma subtype |
WO2008157319A1 (en) * | 2007-06-15 | 2008-12-24 | The Ohio State University Research Foundation | ONCOGENIC ALL-1 FUSION PROTEINS FOR TARGETING DROSHA-MEDIATED microRNA PROCESSING |
JP4517096B2 (ja) * | 2007-07-17 | 2010-08-04 | 愛知県 | 癌の遺伝子治療ベクター及び癌治療用医薬組成物 |
WO2009012263A2 (en) * | 2007-07-18 | 2009-01-22 | The Trustees Of Columbia University In The City Of New York | Tissue-specific micrornas and compositions and uses thereof |
BRPI0815383A2 (pt) | 2007-07-31 | 2015-09-08 | Univ Texas | família de micro-rna que modula fibrose e usos da mesma |
AU2008283794B2 (en) | 2007-07-31 | 2014-03-20 | Board Of Regents, The University Of Texas System | Micro-RNAs that control myosin expression and myofiber identity |
WO2009018303A2 (en) * | 2007-07-31 | 2009-02-05 | The Ohio State University Research Foundation | Methods for reverting methylation by targeting dnmt3a and dnmt3b |
CN101835902B (zh) * | 2007-08-03 | 2014-03-26 | 俄亥俄州立大学研究基金会 | 编码ncrna的超保守区域 |
WO2009023525A2 (en) * | 2007-08-09 | 2009-02-19 | Dharmacon, Inc. | Methods of modulating mesenchymal stem cell differentiation |
WO2009021325A1 (en) | 2007-08-10 | 2009-02-19 | British Columbia Cancer Agency Branch | Microrna compositions and methods for the treatment of myelogenous leukemia |
JP5770472B2 (ja) * | 2007-08-22 | 2015-08-26 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションThe Ohio State University Research Foundation | ヒト急性白血病におけるepha7及びerkリン酸化の調節解除を誘発するための方法及び組成物 |
WO2009029681A2 (en) * | 2007-08-27 | 2009-03-05 | The Regents Of The University Of California | Micrornas for inhibiting viral replication |
EP3138926A3 (en) * | 2007-09-06 | 2017-04-05 | The Ohio State University Research Foundation | Microrna signatures in human ovarian cancer |
US8361714B2 (en) * | 2007-09-14 | 2013-01-29 | Asuragen, Inc. | Micrornas differentially expressed in cervical cancer and uses thereof |
NZ583677A (en) | 2007-10-04 | 2012-06-29 | Santaris Pharma As | MicroRNAs comprising Locked Nucleic Acid (LNA) units |
US20100285471A1 (en) * | 2007-10-11 | 2010-11-11 | The Ohio State University Research Foundation | Methods and Compositions for the Diagnosis and Treatment of Esphageal Adenocarcinomas |
US20090186015A1 (en) * | 2007-10-18 | 2009-07-23 | Latham Gary J | Micrornas differentially expressed in lung diseases and uses thereof |
CN102137927B (zh) | 2007-10-26 | 2014-03-12 | 俄亥俄州立大学研究基金会 | 鉴定脆性组氨酸三联体(Fhit)相互作用的方法及其用途 |
AU2008318778B2 (en) * | 2007-10-29 | 2014-10-02 | Regulus Therapeutics Inc. | Targeting microRNAs for the treatment of liver cancer |
BRPI0818901A2 (pt) | 2007-11-09 | 2015-05-12 | Univ Texas | Micro-rnas da família mir-15 modulam sobrevivência de cardiomiócitos e reparo cardíaco |
US20100240058A1 (en) * | 2007-11-23 | 2010-09-23 | Panagene Inc. | MicroRNA Antisense PNAs, Compositions Comprising the Same, and Methods for Using and Evaluating the Same |
WO2009070653A1 (en) * | 2007-11-30 | 2009-06-04 | The Ohio State University Research Foundation | Microrna expression profiling and targeting in peripheral blood in lung cancer |
US8071562B2 (en) * | 2007-12-01 | 2011-12-06 | Mirna Therapeutics, Inc. | MiR-124 regulated genes and pathways as targets for therapeutic intervention |
WO2009092005A2 (en) * | 2008-01-18 | 2009-07-23 | The J. David Gladstone Institutes | Methods of generating cardiomyocytes and cardiac progenitors and compositions |
US8580503B2 (en) * | 2008-01-27 | 2013-11-12 | Rosetta Genomics Ltd. | Methods and compositions for diagnosing complications of pregnancy |
EP2246432A2 (en) | 2008-01-29 | 2010-11-03 | Proyecto de Biomedicina Cima, S.L. | Methods and compositions capable of causing post-transcriptional silencing of gene expression in a synergic manner |
EP2250183A4 (en) * | 2008-02-14 | 2012-07-25 | Michael Paul Marie Gantier | SMALL IMMUNOSTIMULATORY RNAI MOLECULES |
CN102083980A (zh) | 2008-02-21 | 2011-06-01 | 得克萨斯系统大学董事会 | 调节平滑肌增殖和分化的微小rna及其用途 |
JP2011517283A (ja) * | 2008-02-28 | 2011-06-02 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 前立腺関連障害の予後診断及び治療のためのマイクロrnaに基づく方法及び組成物 |
EP2254668A4 (en) * | 2008-02-28 | 2012-08-15 | Univ Ohio State Res Found | MICRORNA SIGNATURES ASSOCIATED WITH HUMAN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND THEIR USE |
EP2268832A2 (en) * | 2008-03-06 | 2011-01-05 | Asuragen, INC. | Microrna markers for recurrence of colorectal cancer |
US8361980B2 (en) | 2008-03-07 | 2013-01-29 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microRNA related diseases |
WO2009117418A2 (en) * | 2008-03-17 | 2009-09-24 | The Board Of Regents Of The University Of Texas System | Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration |
US20100113284A1 (en) * | 2008-04-04 | 2010-05-06 | Alexander Aristarkhov | Small interfering rna (sirna) target site blocking oligos and uses thereof |
WO2009126650A2 (en) * | 2008-04-07 | 2009-10-15 | Cornell Research Foundation, Inc. | Inhibition of angiognesis |
US20090258928A1 (en) * | 2008-04-08 | 2009-10-15 | Asuragen, Inc. | Methods and compositions for diagnosing and modulating human papillomavirus (hpv) |
CN102066405B (zh) * | 2008-04-28 | 2015-09-30 | 哈佛大学校长及研究员协会 | 用于细胞穿透的超荷电蛋白 |
US8916532B2 (en) * | 2008-04-28 | 2014-12-23 | The Trustees Of The University Of Pennsylvania | Methods for enhancing utrophin production via inhibition of microRNA |
WO2009134443A2 (en) * | 2008-05-02 | 2009-11-05 | The Brigham And Women's Hospital, Inc. | Rna-induced translational silencing and cellular apoptosis |
WO2009136693A1 (en) * | 2008-05-06 | 2009-11-12 | Panagene Inc. | Peptide nucleic acid probes, kits and methods for expression profiling of micrornas |
EP2990487A1 (en) | 2008-05-08 | 2016-03-02 | Asuragen, INC. | Compositions and methods related to mirna modulation of neovascularization or angiogenesis |
EP2307028B1 (en) | 2008-06-11 | 2013-10-02 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Use of mir-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy |
ES2563485T3 (es) | 2008-07-01 | 2016-03-15 | Monsanto Technology Llc | Construcciones de ADN recombinante y procedimientos para modular la expresión de un gen diana |
EP2314678B1 (en) | 2008-07-03 | 2017-02-15 | National University Corporation Kobe University | Micro-rna associated with rheumatoid arthritis |
US20100003674A1 (en) * | 2008-07-03 | 2010-01-07 | Cope Frederick O | Adult stem cells, molecular signatures, and applications in the evaluation, diagnosis, and therapy of mammalian conditions |
KR101031305B1 (ko) * | 2008-07-23 | 2011-04-29 | 국립암센터 | 마이크로rna-21 저해제를 포함하는 방사선 민감성증진용 조성물 |
ES2541442T3 (es) | 2008-08-01 | 2015-07-20 | Roche Innovation Center Copenhagen A/S | Modulación mediada por microARN de factores estimulantes de colonias |
US9089610B2 (en) * | 2008-08-19 | 2015-07-28 | Nektar Therapeutics | Complexes of small-interfering nucleic acids |
EP3067359A1 (en) | 2008-09-23 | 2016-09-14 | Scott G. Petersen | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference |
JP6087504B2 (ja) | 2008-11-07 | 2017-03-01 | マサチューセッツ インスティテュート オブ テクノロジー | アミノアルコールリピドイドおよびその使用 |
CN102333888B (zh) * | 2008-12-24 | 2013-07-10 | 姜桥 | 用于肿瘤样本起源组织分类的基因表达签名 |
MX2011008190A (es) | 2009-02-04 | 2011-10-06 | Univ Texas | Direccionamiento dual de mir-208 y mir-499 en el tratamiento de trastornos cardiacos. |
US8362203B2 (en) | 2009-02-10 | 2013-01-29 | Wayne State University | Non-natural peptides as models for the development of antibiotics |
IE20090047A1 (en) * | 2009-02-26 | 2010-09-29 | Nat Univ Ireland | Protein targets in disease |
WO2010103522A1 (en) * | 2009-03-10 | 2010-09-16 | Rosetta Genomics Ltd. | Method for detection of nucleic acid sequences |
SG174455A1 (en) * | 2009-03-19 | 2011-10-28 | Agency Science Tech & Res | Modulators of apoptosis and the uses thereof |
US9034837B2 (en) | 2009-04-24 | 2015-05-19 | Roche Innovation Center Copenhagen A/S | Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon |
WO2010129023A2 (en) | 2009-04-28 | 2010-11-11 | President And Fellows Of Harvard College | Supercharged proteins for cell penetration |
WO2010129791A1 (en) | 2009-05-06 | 2010-11-11 | University Of Medicine And Dentistry Of New Jersey | Rna targeting in alpha-synucleinopathies |
US20130177624A1 (en) * | 2009-05-08 | 2013-07-11 | David Brian Corry | Mirna expression in allergic disease |
CN102549158B (zh) * | 2009-05-22 | 2017-09-26 | 库尔纳公司 | 通过抑制针对转录因子e3(tfe3)的天然反义转录物来治疗tfe3和胰岛素受体底物蛋白2(irs2)相关的疾病 |
CN103223176B (zh) * | 2009-05-26 | 2015-03-25 | 中国科学院上海生命科学研究院 | miR-24及其抑制剂的应用 |
WO2011028550A1 (en) * | 2009-08-24 | 2011-03-10 | Merck Sharp & Dohme Corp. | Segmented micro rna mimetics |
WO2011035065A1 (en) | 2009-09-17 | 2011-03-24 | Nektar Therapeutics | Monoconjugated chitosans as delivery agents for small interfering nucleic acids |
US20150025122A1 (en) | 2009-10-12 | 2015-01-22 | Larry J. Smith | Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro |
CN102803511A (zh) | 2009-11-23 | 2012-11-28 | 俄亥俄州立大学 | 用于影响肿瘤细胞生长、迁移和侵袭的材料和方法 |
SI2506857T1 (en) | 2009-12-01 | 2018-08-31 | Translate Bio, Inc. | Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases |
EP2336171A1 (en) | 2009-12-11 | 2011-06-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Novel targets for the treatment of proliferative diseases |
US20120315640A1 (en) | 2009-12-21 | 2012-12-13 | Hidetoshi Tahara | Senescence marker, method for evaluating senescence inhibitor, and cancer inhibitor |
WO2011088309A1 (en) | 2010-01-14 | 2011-07-21 | Regulus Therapeutics Inc. | Microrna compositions and methods |
WO2011088435A1 (en) | 2010-01-15 | 2011-07-21 | Cornell University | Methods for reducing protein levels in a cell |
JPWO2011126105A1 (ja) * | 2010-04-08 | 2013-07-11 | 啓之 吉富 | 免疫系の異常疾患または関節系の異常疾患への罹患またはこれらの病勢を判定するための検査方法 |
US9145556B2 (en) | 2010-04-13 | 2015-09-29 | Life Technologies Corporation | Compositions and methods for inhibition of nucleic acids function |
CA2795815C (en) | 2010-04-23 | 2018-06-26 | Cold Spring Harbor Laboratory | Novel structurally designed shrnas |
US9320756B2 (en) * | 2010-05-07 | 2016-04-26 | Centre National De La Recherche Scientifique | UCP1 (thermogenin)—inducing agents for use in the treatment of a disorder of the energy homeostasis |
US20130150256A1 (en) | 2010-06-11 | 2013-06-13 | Jane Synnergren | Novel micrornas for the detection and isolation of human embryonic stem cell-derived cardiac cell types |
NZ605420A (en) | 2010-07-06 | 2015-02-27 | Interna Technologies Bv | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
CN103180461A (zh) * | 2010-07-25 | 2013-06-26 | 纽约大学 | 用于间皮瘤预后的组合物和方法 |
EP2608812B1 (en) | 2010-08-25 | 2018-08-15 | The General Hospital Corporation | Nucleic acids targeting mir-33 micrornas for regulating lipid metabolism |
US9193827B2 (en) | 2010-08-26 | 2015-11-24 | Massachusetts Institute Of Technology | Poly(beta-amino alcohols), their preparation, and uses thereof |
US20130210901A1 (en) * | 2010-09-20 | 2013-08-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of treating neurodegenerative diseases |
WO2012041959A1 (en) | 2010-09-30 | 2012-04-05 | University Of Zurich | Treatment of b-cell lymphoma with microrna |
WO2012045894A1 (es) | 2010-10-05 | 2012-04-12 | Proyecto De Biomedicina Cima, S.L. | Compuestos y composiciones para el tratamiento de enfermedades debidas a la infección por el virus de la hepatitis b |
EP2637673B1 (en) | 2010-11-12 | 2016-10-26 | The Ohio State University Research Foundation | Methods related to microrna-21 and mismatch repair in colorectal cancer |
EP2640368B1 (en) | 2010-11-15 | 2020-12-30 | The Ohio State University Research Foundation | Controlled release mucoadhesive systems |
WO2012077819A1 (ja) | 2010-12-10 | 2012-06-14 | 国立大学法人 東京工業大学 | 標的核酸の検出方法及びキット |
EA201370139A1 (ru) | 2010-12-15 | 2013-10-30 | Мираген Терапеутикс | Ингибиторы микро-рнк, содержащие закрытые нуклеотиды |
US8455518B2 (en) | 2010-12-28 | 2013-06-04 | Avon Products, Inc. | Method of treating skin with microRNA modulators |
EP2474617A1 (en) | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
EP2663323B1 (en) * | 2011-01-14 | 2017-08-16 | The General Hospital Corporation | Methods targeting mir-128 for regulating cholesterol/lipid metabolism |
CN106924216A (zh) | 2011-01-24 | 2017-07-07 | 安特里奥公司 | 纳米颗粒组合物、其制剂和它们的用途 |
ES2720648T3 (es) | 2011-01-24 | 2019-07-23 | Anterios Inc | Composiciones de nanopartículas |
AU2012212105A1 (en) | 2011-02-03 | 2013-09-12 | Mirna Therapeutics, Inc. | Synthetic mimics of miR-124 |
SG10201600836PA (en) | 2011-02-03 | 2016-03-30 | Mirna Therapeutics Inc | Synthetic mimics of mir-34 |
CA2827380C (en) | 2011-02-12 | 2020-08-25 | University Of Iowa Research Foundation | Therapeutic nucleic acids |
JP2014509852A (ja) | 2011-03-07 | 2014-04-24 | ジ・オハイオ・ステート・ユニバーシティ | マイクロRNA−155(miR−155)により誘導される変異誘発活性は炎症および癌を結び付ける |
US9238716B2 (en) | 2011-03-28 | 2016-01-19 | Massachusetts Institute Of Technology | Conjugated lipomers and uses thereof |
EP2508607A1 (en) | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
LT2702155T (lt) | 2011-04-25 | 2017-05-10 | Regulus Therapeutics Inc. | Mikro rnr junginiai ir būdai mir-21 aktyvumo moduliavimui |
IL307511A (en) | 2011-06-08 | 2023-12-01 | Shire Human Genetic Therapies | Preparations of lipid nanoparticles and methods for administration of mRNA |
EP3564393A1 (en) | 2011-06-21 | 2019-11-06 | Alnylam Pharmaceuticals, Inc. | Assays and methods for determining activity of a therapeutic agent in a subject |
KR101938548B1 (ko) * | 2011-06-23 | 2019-01-15 | (주)아모레퍼시픽 | 마이크로 rna를 포함하는 색소형성유전자 발현조절용 조성물 |
US20140274789A1 (en) * | 2011-08-11 | 2014-09-18 | Andreas Keller | Complex sets of mirnas as non-invasive biomarkers for psoriasis |
US9644241B2 (en) | 2011-09-13 | 2017-05-09 | Interpace Diagnostics, Llc | Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease |
KR20140091688A (ko) | 2011-10-06 | 2014-07-22 | 미라젠 세러퓨틱스 인코포레이티드 | 마이크로rna 조절에 의한 전신 에너지 항상성의 제어 |
EP2766500A4 (en) | 2011-10-14 | 2015-10-14 | Univ Ohio State | METHODS AND MATERIALS RELATED TO OVARIAN CANCER |
PE20181541A1 (es) | 2011-10-27 | 2018-09-26 | Massachusetts Inst Technology | Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco |
WO2013067050A1 (en) | 2011-10-31 | 2013-05-10 | University Of Utah Research Foundation | Genetic alterations in glioblastoma |
JP2015501843A (ja) | 2011-12-13 | 2015-01-19 | オハイオ・ステイト・イノベーション・ファウンデーション | miR−21およびmiR−29a、エキソソーム阻害、およびがん転移に関する方法および組成物 |
EP2791210A1 (en) | 2011-12-16 | 2014-10-22 | Massachusetts Institute of Technology | Alpha-aminoamidine polymers and uses thereof |
LT2791160T (lt) | 2011-12-16 | 2022-06-10 | Modernatx, Inc. | Modifikuotos mrnr sudėtys |
ITRM20110685A1 (it) * | 2011-12-23 | 2013-06-24 | Internat Ct For Genetic En Gineering And | Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci |
CA2866052A1 (en) | 2012-01-20 | 2013-07-25 | The Ohio State University | Breast cancer biomarker signatures for invasiveness and prognosis |
US20150148405A1 (en) * | 2012-02-21 | 2015-05-28 | The Johns Hopkins University | Expression Construct for a Lin28-Resistant Let-7 Precursor MicroRNA |
CA2868391A1 (en) | 2012-04-02 | 2013-10-10 | Stephane Bancel | Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same |
US9192651B2 (en) | 2012-04-02 | 2015-11-24 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
WO2013152230A1 (en) | 2012-04-04 | 2013-10-10 | The Trustees Of Columbia University In The City Of New York | Smooth muscle specific inhibition for anti-restenotic therapy |
EP2841579B1 (en) | 2012-04-25 | 2018-10-10 | Regulus Therapeutics Inc. | Microrna compounds and methods for modulating mir-21 activity |
CN104394892B (zh) * | 2012-05-15 | 2020-02-14 | 北京命码生科科技有限公司 | 植物作为功能microRNA和/或功能siRNA运载体、制备方法及其应用 |
WO2013185067A1 (en) | 2012-06-08 | 2013-12-12 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
MX355408B (es) | 2012-06-21 | 2018-04-18 | Miragen Therapeutics Inc | Inhibidores a base de oligonucleotidos que comprenden un motivo de acido nucleico bloqueado. |
US9163235B2 (en) | 2012-06-21 | 2015-10-20 | MiRagen Therapeutics, Inc. | Inhibitors of the miR-15 family of micro-RNAs |
UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
WO2014081507A1 (en) | 2012-11-26 | 2014-05-30 | Moderna Therapeutics, Inc. | Terminally modified rna |
EP2931319B1 (en) | 2012-12-13 | 2019-08-21 | ModernaTX, Inc. | Modified nucleic acid molecules and uses thereof |
US9416369B2 (en) | 2012-12-18 | 2016-08-16 | University Of Washington Through Its Center For Commercialization | Methods and compositions to modulate RNA processing |
AU2013374345A1 (en) | 2013-01-17 | 2015-08-06 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
WO2014134509A2 (en) | 2013-02-28 | 2014-09-04 | University Of Massachusetts | Peptide-and amine-modified glucan particles for delivery of therapeutic cargoes |
EP2774996B1 (en) * | 2013-03-04 | 2016-08-10 | Technische Universität Kaiserslautern | A method for production of single-stranded nucleic acids |
WO2014159813A1 (en) | 2013-03-13 | 2014-10-02 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
EA201591229A1 (ru) | 2013-03-14 | 2016-01-29 | Шир Хьюман Дженетик Терапис, Инк. | Способы очистки матричной рнк |
DK2968586T3 (en) | 2013-03-14 | 2018-10-08 | Translate Bio Inc | CFTR MRNA COMPOSITIONS AND RELATED PROCEDURES AND APPLICATIONS |
WO2014145123A2 (en) | 2013-03-15 | 2014-09-18 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State Unversity | Peptide array quality control |
US10138507B2 (en) | 2013-03-15 | 2018-11-27 | Modernatx, Inc. | Manufacturing methods for production of RNA transcripts |
US9752143B2 (en) | 2013-03-15 | 2017-09-05 | MiRagen Therapeutics, Inc. | Locked nucleic acid inhibitor of miR-145 and uses thereof |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2014144383A1 (en) | 2013-03-15 | 2014-09-18 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Non-covalent patterned chemical features and use thereof in maldi-based quality control |
WO2014179562A1 (en) | 2013-05-01 | 2014-11-06 | Massachusetts Institute Of Technology | 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof |
JP7019233B2 (ja) | 2013-07-11 | 2022-02-15 | モデルナティエックス インコーポレイテッド | CRISPR関連タンパク質をコードする合成ポリヌクレオチドおよび合成sgRNAを含む組成物ならびに使用方法 |
AU2014315287A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
CA2926218A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
EP3574923A1 (en) | 2013-10-22 | 2019-12-04 | Translate Bio, Inc. | Mrna therapy for phenylketonuria |
WO2015061500A1 (en) | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Mrna therapy for argininosuccinate synthetase deficiency |
CN112656954A (zh) | 2013-10-22 | 2021-04-16 | 夏尔人类遗传性治疗公司 | 用于递送信使rna的脂质制剂 |
WO2015104706A1 (en) | 2014-01-08 | 2015-07-16 | Hadasit Medical Research Services And Development Ltd. | Mir-122* as an active micro-rna, compositions comprising the same and uses thereof |
CA2936157C (en) * | 2014-01-15 | 2021-08-24 | Tokyo Institute Of Technology | Covered sequence conversion dna and detection methods |
KR20220158867A (ko) | 2014-04-25 | 2022-12-01 | 샤이어 휴먼 지네틱 테라피즈 인크. | 메신저 rna 의 정제 방법 |
CA2949437C (en) | 2014-05-20 | 2023-08-15 | University Of Iowa Research Foundation | Huntington's disease therapeutic compounds |
ES2750686T3 (es) | 2014-05-30 | 2020-03-26 | Translate Bio Inc | Lípidos biodegradables para la administración de ácidos nucleicos |
KR102559979B1 (ko) | 2014-06-24 | 2023-07-25 | 샤이어 휴먼 지네틱 테라피즈 인크. | 핵산의 전달용 입체화학적으로 풍부한 조성물 |
WO2016004202A1 (en) | 2014-07-02 | 2016-01-07 | Massachusetts Institute Of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
EP3169693B1 (en) | 2014-07-16 | 2022-03-09 | ModernaTX, Inc. | Chimeric polynucleotides |
US20170210788A1 (en) | 2014-07-23 | 2017-07-27 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
US9376681B2 (en) * | 2014-09-08 | 2016-06-28 | MiRagen Therapeutics, Inc. | miR-29 mimics and uses thereof |
WO2016059474A2 (en) | 2014-10-14 | 2016-04-21 | Abbott Japan Co., Ltd | Sequence conversion and signal amplifier dna having poly dna spacer sequences and detection methods using same |
WO2016069717A1 (en) * | 2014-10-28 | 2016-05-06 | MiRagen Therapeutics, Inc. | Inhibitors of mirnas in regulation of arterial stiffness and uses thereof |
WO2016077125A1 (en) | 2014-11-10 | 2016-05-19 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules containing reduced uracil content and uses thereof |
DK3218386T3 (da) | 2014-11-14 | 2021-06-07 | Voyager Therapeutics Inc | Modulatorisk polynukleotid |
KR102599909B1 (ko) | 2014-11-14 | 2023-11-09 | 보이저 테라퓨틱스, 인크. | 근위축성 측삭 경화증(als)을 치료하는 조성물 및 방법 |
CN108064312B (zh) | 2014-12-24 | 2022-04-08 | 雅培实验室 | 基于具有靶扩增的信号放大dna级联反应的检测方法 |
US20180021364A1 (en) | 2015-01-16 | 2018-01-25 | Voyager Therapeutics, Inc. | Central nervous system targeting polynucleotides |
SG11201705907XA (en) | 2015-01-20 | 2017-08-30 | Miragen Therapeutics Inc | Mir-92 inhibitors and uses thereof |
ES2808750T3 (es) | 2015-04-03 | 2021-03-01 | Univ Massachusetts | Compuestos oligonucleotídicos dirigidos a ARNm de huntingtina |
EP3277815B1 (en) | 2015-04-03 | 2021-09-22 | University of Massachusetts | Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders |
EP3303590A4 (en) | 2015-06-05 | 2019-01-02 | Miragen Therapeutics, Inc. | Mir-155 inhibitors for treating cutaneous t cell lymphoma (ctcl) |
US10633653B2 (en) | 2015-08-14 | 2020-04-28 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
DK3350333T3 (da) | 2015-09-17 | 2022-01-31 | Modernatx Inc | Polynukleotider, der indeholder en stabiliserende haleregion |
TWI696703B (zh) * | 2015-09-30 | 2020-06-21 | 中央研究院 | 用以診斷心肌梗塞的方法及套組 |
US10188750B1 (en) | 2015-10-23 | 2019-01-29 | University Of South Florida | Self-replicating cell selective gene delivery compositions, methods, and uses thereof |
US20180230489A1 (en) | 2015-10-28 | 2018-08-16 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
US20210206818A1 (en) | 2016-01-22 | 2021-07-08 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
US10478503B2 (en) | 2016-01-31 | 2019-11-19 | University Of Massachusetts | Branched oligonucleotides |
EP3443001A4 (en) | 2016-04-11 | 2020-04-29 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
DK3458083T3 (da) | 2016-05-18 | 2023-01-30 | Modernatx Inc | Polynukleotider, der koder for interleukin-12 (il12), og anvendelser heraf |
EP3458104A1 (en) | 2016-05-18 | 2019-03-27 | Modernatx, Inc. | Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria |
SG11201810162PA (en) | 2016-05-18 | 2018-12-28 | Modernatx Inc | Polynucleotides encoding citrin for the treatment of citrullinemia type 2 |
US20190298657A1 (en) | 2016-05-18 | 2019-10-03 | Modernatx, Inc. | Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency |
AU2017267665C1 (en) | 2016-05-18 | 2023-10-05 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
US20190275170A1 (en) | 2016-05-18 | 2019-09-12 | Modernatx, Inc. | Polynucleotides encoding jagged1 for the treatment of alagille syndrome |
EP3458590B9 (en) | 2016-05-18 | 2021-08-18 | ModernaTX, Inc. | Polynucleotides encoding -galactosidase a for the treatment of fabry disease |
EP3458105B1 (en) | 2016-05-18 | 2024-01-17 | Modernatx, Inc. | Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1 |
CA3024449A1 (en) | 2016-05-18 | 2017-11-23 | Voyager Therapeutics, Inc. | Compositions and methods of treating huntington's disease |
CA3027201A1 (en) | 2016-06-14 | 2017-12-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
US11564997B2 (en) | 2016-06-29 | 2023-01-31 | Crispr Therapeutics Ag | Materials and methods for treatment of friedreich ataxia and other related disorders |
EP3478829A1 (en) | 2016-06-29 | 2019-05-08 | Crispr Therapeutics AG | Materials and methods for treatment of myotonic dystrophy type 1 (dm1) and other related disorders |
US11174469B2 (en) | 2016-06-29 | 2021-11-16 | Crispr Therapeutics Ag | Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders |
AU2017292169B2 (en) | 2016-07-06 | 2021-12-23 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of pain related disorders |
US11459587B2 (en) | 2016-07-06 | 2022-10-04 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of pain related disorders |
EP3496758A4 (en) | 2016-08-12 | 2020-11-11 | University of Massachusetts | CONJUGATE OLIGONUCLEOTIDES |
KR20190086681A (ko) | 2016-10-26 | 2019-07-23 | 모더나티엑스, 인크. | 면역 반응을 향상시키기 위한 메신저 리보핵산 및 그의 사용 방법 |
US11236337B2 (en) | 2016-11-01 | 2022-02-01 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
CA3042401A1 (en) * | 2016-11-01 | 2018-05-11 | The Research Foundation For The State University Of New York | 5-halouracil-modified micrornas and their use in the treatment of cancer |
EP3538067A1 (en) | 2016-11-08 | 2019-09-18 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
WO2018089861A1 (en) * | 2016-11-11 | 2018-05-17 | The Regents Of The University Of California | Methods and compositions for the treatment of cancer and metabolic diseases |
BR112019015797A2 (pt) | 2017-02-01 | 2020-03-17 | Modernatx, Inc. | Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação |
JP2020508056A (ja) | 2017-02-22 | 2020-03-19 | クリスパー・セラピューティクス・アクチェンゲゼルシャフトCRISPR Therapeutics AG | 遺伝子編集のための組成物および方法 |
WO2018154462A2 (en) | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders |
US11559588B2 (en) | 2017-02-22 | 2023-01-24 | Crispr Therapeutics Ag | Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders |
WO2018154418A1 (en) | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders |
MX2019010155A (es) | 2017-02-27 | 2020-12-10 | Translate Bio Inc | Arnm de cftr optimizado por codón novedoso. |
AU2018240515A1 (en) | 2017-03-24 | 2019-08-01 | CureVac SE | Nucleic acids encoding CRISPR-associated proteins and uses thereof |
AU2018261003A1 (en) | 2017-05-05 | 2019-11-14 | Voyager Therapeutics, Inc. | Compositions and methods of treating Huntington's Disease |
US11603542B2 (en) | 2017-05-05 | 2023-03-14 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
AU2018268859A1 (en) | 2017-05-16 | 2019-12-12 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding CFTR |
JP7285220B2 (ja) | 2017-05-18 | 2023-06-01 | モデルナティエックス インコーポレイテッド | 連結したインターロイキン-12(il12)ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子 |
ES2952779T3 (es) | 2017-05-18 | 2023-11-06 | Modernatx Inc | ARN mensajero modificado que comprende elementos de ARN funcionales |
WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
TWI804518B (zh) | 2017-10-16 | 2023-06-11 | 美商航海家醫療公司 | 肌萎縮性脊髓側索硬化症(als)之治療 |
WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
WO2019084229A1 (en) | 2017-10-27 | 2019-05-02 | Massachusetts Institute Of Technology | POLY (BETA-AMINO ESTERS) AND USES THEREOF |
US20190153440A1 (en) | 2017-11-21 | 2019-05-23 | Casebia Therapeutics Llp | Materials and methods for treatment of autosomal dominant retinitis pigmentosa |
MA50802A (fr) | 2017-11-22 | 2020-09-30 | Modernatx Inc | Polynucléotides codant pour des sous-unités alpha et bêta de propionyl-coa carboxylase pour le traitement de l'acidémie propionique |
US11859215B2 (en) | 2017-11-22 | 2024-01-02 | Modernatx, Inc. | Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders |
JP7423521B2 (ja) | 2017-11-22 | 2024-01-29 | モダーナティエックス・インコーポレイテッド | フェニルケトン尿症の治療用のフェニルアラニンヒドロキシラーゼをコードするポリヌクレオチド |
WO2019118919A1 (en) | 2017-12-15 | 2019-06-20 | Flagship Pioneering, Inc. | Compositions comprising circular polyribonucleotides and uses thereof |
CN111836892A (zh) | 2017-12-21 | 2020-10-27 | 克里斯珀医疗股份公司 | 用于治疗2a型乌谢尔综合征的材料和方法 |
US11802146B2 (en) | 2018-01-05 | 2023-10-31 | Modernatx, Inc. | Polynucleotides encoding anti-chikungunya virus antibodies |
JP2021512090A (ja) | 2018-01-30 | 2021-05-13 | モデルナティーエックス, インコーポレイテッド | 免疫細胞に薬剤を送達するための組成物及び方法 |
EP3762500A1 (en) | 2018-03-06 | 2021-01-13 | Voyager Therapeutics, Inc. | Insect cell manufactured partial self-complementary aav genomes |
WO2019200171A1 (en) | 2018-04-11 | 2019-10-17 | Modernatx, Inc. | Messenger rna comprising functional rna elements |
WO2019222441A1 (en) | 2018-05-16 | 2019-11-21 | Voyager Therapeutics, Inc. | Aav serotypes for brain specific payload delivery |
EP3793615A2 (en) | 2018-05-16 | 2021-03-24 | Voyager Therapeutics, Inc. | Directed evolution of aav to improve tropism for cns |
US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
WO2020023390A1 (en) | 2018-07-25 | 2020-01-30 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
MX2021001590A (es) | 2018-08-10 | 2021-07-02 | Univ Massachusetts | Oligonucleótidos modificados dirigidos a snp. |
WO2020041793A1 (en) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Methods for purification of messenger rna |
EP3846776A1 (en) | 2018-09-02 | 2021-07-14 | ModernaTX, Inc. | Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency |
MA53608A (fr) | 2018-09-13 | 2021-07-21 | Modernatx Inc | Polynucléotides codant pour les sous-unités e1-alpha, e1-beta et e2 du complexe alpha-cétoacide déshydrogénase à chaîne ramifiée pour le traitement de la leucinose |
US20230009009A1 (en) | 2018-09-13 | 2023-01-12 | Modernatx, Inc. | Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease |
EP3850102A1 (en) | 2018-09-14 | 2021-07-21 | ModernaTX, Inc. | Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome |
AU2019338535A1 (en) | 2018-09-14 | 2021-04-15 | Modernatx, Inc. | Methods and compositions for treating cancer using mRNA therapeutics |
JP2022501367A (ja) | 2018-09-20 | 2022-01-06 | モデルナティエックス インコーポレイテッドModernaTX, Inc. | 脂質ナノ粒子の調製及びその投与方法 |
WO2020069169A1 (en) | 2018-09-27 | 2020-04-02 | Modernatx, Inc. | Polynucleotides encoding arginase 1 for the treatment of arginase deficiency |
EP3870600A1 (en) | 2018-10-24 | 2021-09-01 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
US11608412B2 (en) | 2018-10-26 | 2023-03-21 | Massachusetts Institute Of Technology | Polymer-lipids and compositions |
WO2020112736A1 (en) * | 2018-11-30 | 2020-06-04 | Dow Agrosciences Llc | Extension sequences for rna inhibitory molecules |
EP3897702A2 (en) | 2018-12-21 | 2021-10-27 | CureVac AG | Rna for malaria vaccines |
MX2021009245A (es) | 2019-01-31 | 2021-11-12 | Modernatx Inc | Metodos de preparacion de nanoparticulas lipidicas. |
EP3920950A1 (en) | 2019-02-08 | 2021-12-15 | CureVac AG | Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases |
KR20210135265A (ko) | 2019-03-04 | 2021-11-12 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 원형 폴리리보뉴클레오티드 및 그의 약제학적 조성물 |
EP3946466A2 (en) | 2019-03-25 | 2022-02-09 | Flagship Pioneering Innovations VI, LLC | Compositions comprising modified circular polyribonucleotides and uses thereof |
EP3966328A4 (en) | 2019-05-06 | 2023-10-18 | University Of Massachusetts | ANTI-C9ORF72 OLIGONUCLEOTIDES AND RELATED METHODS |
EP3965830A1 (en) | 2019-05-07 | 2022-03-16 | ModernaTX, Inc. | Differentially expressed immune cell micrornas for regulation of protein expression |
JP2022531461A (ja) | 2019-05-07 | 2022-07-06 | モデルナティエックス インコーポレイテッド | 免疫細胞活性を破壊するポリヌクレオチド及びその使用方法 |
US20220226438A1 (en) | 2019-05-08 | 2022-07-21 | Astrazeneca Ab | Compositions for skin and wounds and methods of use thereof |
WO2020252436A1 (en) | 2019-06-14 | 2020-12-17 | Flagship Pioneering Innovations Vi, Llc | Circular rnas for cellular therapy |
EP3986452A1 (en) | 2019-06-18 | 2022-04-27 | CureVac AG | Rotavirus mrna vaccine |
MA56538A (fr) | 2019-06-19 | 2022-04-27 | Flagship Pioneering Innovations Vi Llc | Procédés de dosage de polyribonucléotides circulaires |
WO2020257730A1 (en) | 2019-06-19 | 2020-12-24 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising circular polyribonucleotides for protein modulation and uses thereof |
WO2020263883A1 (en) | 2019-06-24 | 2020-12-30 | Modernatx, Inc. | Endonuclease-resistant messenger rna and uses thereof |
EP3986480A1 (en) | 2019-06-24 | 2022-04-27 | ModernaTX, Inc. | Messenger rna comprising functional rna elements and uses thereof |
BR112022001947A2 (pt) | 2019-08-14 | 2022-09-20 | Curevac Ag | Combinações e composições de rna com propriedades imunoestimuladoras reduzidas |
WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
US20240123034A1 (en) | 2019-10-15 | 2024-04-18 | Modernatx, Inc. | Mrnas encoding granulocyte-macrophage colony stimulating factor for treating parkinson's disease |
CN110791560B (zh) * | 2019-11-06 | 2021-09-14 | 中国医学科学院医药生物技术研究所 | 一种用于阿尔茨海默病诊断和/或治疗的miRNA标志物 |
CN115361954A (zh) | 2020-01-29 | 2022-11-18 | 旗舰创业创新第六有限责任公司 | 用于翻译的组合物及其使用方法 |
WO2021155274A1 (en) | 2020-01-31 | 2021-08-05 | Modernatx, Inc. | Methods of preparing lipid nanoparticles |
DE112021000012B4 (de) | 2020-02-04 | 2023-08-31 | CureVac SE | Coronavirus-Vakzine |
US20230173104A1 (en) | 2020-05-14 | 2023-06-08 | Modernatx, Inc. | Lnp compositions comprising an mrna therapeutic and an effector molecule |
WO2021236952A1 (en) | 2020-05-20 | 2021-11-25 | Flagship Pioneering, Inc. | Compositions and methods for producing human polyclonal antibodies |
CA3179420A1 (en) | 2020-05-20 | 2021-11-25 | Avak Kahvejian | Coronavirus antigen compositions and their uses |
EP4153223A1 (en) | 2020-05-20 | 2023-03-29 | Flagship Pioneering Innovations VI, LLC | Immunogenic compositions and uses thereof |
EP3993828A1 (en) | 2020-05-29 | 2022-05-11 | CureVac AG | Nucleic acid based combination vaccines |
AU2021285812A1 (en) | 2020-06-01 | 2023-01-05 | Modernatx, Inc. | Phenylalanine hydroxylase variants and uses thereof |
MX2022016550A (es) | 2020-06-23 | 2023-04-10 | Modernatx Inc | Composiciones de lnp que comprenden agentes terapeuticos de mrna con semivida extendida. |
EP4185274A1 (en) | 2020-07-24 | 2023-05-31 | Strand Therapeutics Inc. | Lipidnanoparticle comprising modified nucleotides |
IL300404A (en) | 2020-08-06 | 2023-04-01 | Modernatx Inc | Methods for preparing fat nanoparticles |
US20240066114A1 (en) | 2020-08-31 | 2024-02-29 | CureVac SE | Multivalent nucleic acid based coronavirus vaccines |
AU2021336976A1 (en) | 2020-09-03 | 2023-03-23 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and uses thereof |
WO2022104131A1 (en) | 2020-11-13 | 2022-05-19 | Modernatx, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
WO2022137133A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Rna vaccine against sars-cov-2 variants |
TW202241931A (zh) | 2021-01-08 | 2022-11-01 | 美商斯特蘭德治療股份有限公司 | 表現構築體及其用途 |
CA3170747A1 (en) | 2021-01-27 | 2022-08-04 | Moritz THRAN | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
AU2022220328A1 (en) | 2021-02-12 | 2023-08-17 | Modernatx, Inc. | Lnp compositions comprising payloads for in vivo therapy |
JP2024512026A (ja) | 2021-03-24 | 2024-03-18 | モデルナティエックス インコーポレイテッド | オルニチントランスカルバミラーゼ欠損症の治療を目的とした脂質ナノ粒子及びオルニチントランスカルバミラーゼをコードするポリヌクレオチド |
WO2022204380A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof |
WO2022204390A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof |
WO2022204371A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof |
WO2022204369A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia |
CA3171589A1 (en) | 2021-05-03 | 2022-11-03 | Moritz THRAN | Improved nucleic acid sequence for cell type specific expression |
WO2022266083A2 (en) | 2021-06-15 | 2022-12-22 | Modernatx, Inc. | Engineered polynucleotides for cell-type or microenvironment-specific expression |
WO2022271776A1 (en) | 2021-06-22 | 2022-12-29 | Modernatx, Inc. | Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome |
EP4359539A1 (en) | 2021-06-23 | 2024-05-01 | University Of Massachusetts | Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders |
WO2023031392A2 (en) | 2021-09-03 | 2023-03-09 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine |
AU2022336209A1 (en) | 2021-09-03 | 2024-01-18 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
WO2023056044A1 (en) | 2021-10-01 | 2023-04-06 | Modernatx, Inc. | Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease |
WO2023064469A1 (en) | 2021-10-13 | 2023-04-20 | Modernatx, Inc. | Compositions of mrna-encoded il15 fusion proteins and methods of use thereof |
WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
WO2023183909A2 (en) | 2022-03-25 | 2023-09-28 | Modernatx, Inc. | Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia |
WO2023196399A1 (en) | 2022-04-06 | 2023-10-12 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria |
WO2023212618A1 (en) | 2022-04-26 | 2023-11-02 | Strand Therapeutics Inc. | Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof |
WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
WO2024026475A1 (en) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses |
WO2024026482A1 (en) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Lipid nanoparticle compositions comprising surface lipid derivatives and related uses |
WO2024026487A1 (en) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Lipid nanoparticle compositions comprising phospholipid derivatives and related uses |
WO2024059904A1 (en) * | 2022-09-20 | 2024-03-28 | The Council Of The Queensland Institute Of Medical Research | Anti-fibrotic microrna composition |
WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5436141A (en) | 1989-02-24 | 1995-07-25 | University Of Medicine And Dentistry Of New Jersey | Method for synthesizing stable single-stranded CDNA in eukaryotes by means of a bacterial retron and products |
US5849563A (en) | 1989-02-24 | 1998-12-15 | The University Of Medecine And Dentistry Of New Jersey | Eukaryotes expressing single stranded hybrid molecules |
US5780269A (en) | 1989-02-24 | 1998-07-14 | The University Of Medicine And Denistry Of New Jersey | Hybrid molecules |
US5861310A (en) * | 1993-11-03 | 1999-01-19 | Dana-Farber Cancer Institute | Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor |
US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
US6207373B1 (en) | 1998-02-25 | 2001-03-27 | Nanogen, Inc. | Methods for determining nature of repeat units in DNA |
US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
EP1053319A2 (en) * | 1998-01-28 | 2000-11-22 | Chiron Corporation | Human genes and gene expression products ii |
US6821724B1 (en) * | 1998-09-17 | 2004-11-23 | Affymetrix, Inc. | Methods of genetic analysis using nucleic acid arrays |
AU2002210791A1 (en) | 2000-07-28 | 2002-02-13 | Compugen Inc. | Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome |
US6905827B2 (en) * | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
WO2005118806A2 (en) | 2004-05-28 | 2005-12-15 | Ambion, Inc. | METHODS AND COMPOSITIONS INVOLVING MicroRNA |
CA2850323A1 (en) | 2004-11-12 | 2006-12-28 | Asuragen, Inc. | Methods and compositions involving mirna and mirna inhibitor molecules |
-
2002
- 2002-09-27 CA CA2937159A patent/CA2937159C/en not_active Expired - Fee Related
- 2002-09-27 WO PCT/EP2002/010881 patent/WO2003029459A2/en active Application Filing
- 2002-09-27 EP EP02782801.1A patent/EP1430128B1/en not_active Expired - Lifetime
- 2002-09-27 US US10/490,955 patent/US7232806B2/en not_active Expired - Lifetime
- 2002-09-27 EP EP11175595.5A patent/EP2428569B1/en not_active Expired - Lifetime
- 2002-09-27 EP EP11175536.9A patent/EP2385122B1/en not_active Expired - Lifetime
- 2002-09-27 EP EP11175566.6A patent/EP2428568B1/en not_active Expired - Lifetime
- 2002-09-27 EP EP11175570.8A patent/EP2385123B1/en not_active Expired - Lifetime
- 2002-09-27 EP EP11175572A patent/EP2390328A1/en not_active Ceased
- 2002-09-27 EP EP11175601.1A patent/EP2428571B1/en not_active Expired - Lifetime
- 2002-09-27 EP EP11175598.9A patent/EP2428570B1/en not_active Expired - Lifetime
- 2002-09-27 JP JP2003532675A patent/JP4371812B2/ja not_active Expired - Fee Related
- 2002-09-27 EP EP11175590.6A patent/EP2390330B1/en not_active Expired - Lifetime
- 2002-09-27 EP EP11175529.4A patent/EP2428567B1/en not_active Expired - Lifetime
- 2002-09-27 EP EP11175577.3A patent/EP2390329B1/en not_active Expired - Lifetime
- 2002-09-27 AU AU2002347035A patent/AU2002347035B2/en not_active Ceased
- 2002-09-27 EP EP11175534.4A patent/EP2447370B1/en not_active Expired - Lifetime
- 2002-09-27 EP EP11175587.2A patent/EP2386637B1/en not_active Expired - Lifetime
- 2002-09-27 CA CA2462144A patent/CA2462144C/en not_active Expired - Lifetime
- 2002-09-27 IL IL16110002A patent/IL161100A0/xx unknown
- 2002-09-27 EP EP11175608.6A patent/EP2390331B1/en not_active Expired - Lifetime
- 2002-09-27 EP EP10155080.4A patent/EP2224003B1/en not_active Expired - Lifetime
-
2004
- 2004-03-25 IL IL161100A patent/IL161100A/en not_active IP Right Cessation
-
2007
- 2007-05-11 US US11/747,409 patent/US7723510B1/en not_active Expired - Lifetime
-
2009
- 2009-01-23 US US12/358,331 patent/US8222394B2/en not_active Expired - Fee Related
- 2009-06-30 JP JP2009155226A patent/JP5473432B2/ja not_active Expired - Lifetime
- 2009-08-31 US US12/550,704 patent/US7838664B2/en not_active Expired - Fee Related
- 2009-08-31 US US12/550,596 patent/US7838662B2/en not_active Expired - Fee Related
- 2009-08-31 US US12/550,602 patent/US7838663B2/en not_active Expired - Fee Related
- 2009-08-31 US US12/550,586 patent/US7838661B2/en not_active Expired - Fee Related
- 2009-08-31 US US12/550,579 patent/US7838660B2/en not_active Expired - Fee Related
-
2010
- 2010-05-07 US US12/775,952 patent/US8198428B2/en not_active Expired - Fee Related
- 2010-05-07 US US12/775,947 patent/US8207326B2/en not_active Expired - Fee Related
-
2012
- 2012-04-19 IL IL219310A patent/IL219310A/en active IP Right Grant
- 2012-05-16 US US13/472,826 patent/US9000144B2/en not_active Expired - Fee Related
-
2013
- 2013-12-02 JP JP2013249347A patent/JP5963735B2/ja not_active Expired - Lifetime
-
2015
- 2015-01-30 US US14/609,492 patent/US9550993B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5963735B2 (ja) | マイクロrna分子 | |
AU2002347035A1 (en) | Micro-RNA molecules | |
AU2013202594B2 (en) | MicroRNA molecules | |
AU2008200680B2 (en) | Micro-RNA molecules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20101228 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120210 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120509 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120514 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120611 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120614 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120709 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120712 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120808 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130208 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130606 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130613 |
|
RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20130627 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130627 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130902 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131202 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140106 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140204 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5473432 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |